TYCHE INDUSTRIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 177.8 INR | -0.56% |
|
0.00% | -4.41% |
| May. 28 | Tyche Industries Limited Recommends Final Dividend | CI |
| May. 28 | Tyche Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 | CI |
| Sales 2022 | 630M 7.55M | Sales 2023 | 756M 9.05M | Capitalization | 1.43B 17.13M |
|---|---|---|---|---|---|
| Net income 2022 | 93M 1.11M | Net income 2023 | 142M 1.7M | EV / Sales 2022 | 1.2 x |
| Net cash position 2022 | 658M 7.88M | Net cash position 2023 | 726M 8.69M | EV / Sales 2023 | 0.93 x |
| P/E ratio 2022 |
15.2
x | P/E ratio 2023 |
10.1
x | Employees | 166 |
| Yield 2022 |
1.09% | Yield 2023 |
1.43% | Free-Float | 28.22% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.56% | ||
| Current month | -0.31% | ||
| 1 month | +6.98% | ||
| 3 months | -1.36% | ||
| 6 months | -7.25% | ||
| Current year | -4.41% |
1 week
175.75
181.00
1 month
160.10187.90
Current year
148.60230.00
1 year
148.60230.00
3 years
105.00230.00
5 years
35.95349.90
10 years
17.55349.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 98-11-13 | |
Y. Srinivasa Rao
DFI | Director of Finance/CFO | - | 17-05-29 |
| Compliance Officer | - | 23-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 98-11-13 | |
| Director/Board Member | 39 | 14-08-10 | |
| Director/Board Member | 49 | 19-03-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-04 | 177.8 | -0.56% | 1 515 |
| 24-07-03 | 178.8 | -0.17% | 2,226 |
| 24-07-02 | 179.1 | +0.70% | 6,077 |
| 24-07-01 | 177.8 | -0.28% | 4,833 |
| 24-06-28 | 178.4 | +0.31% | 4,865 |
Delayed Quote Bombay S.E., July 04, 2024 at 01:15 am EDT
More quotes
Tyche Industries Limited is an India-based company engaged in manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates of APIs. The Company operates through the Bulk Drugs segment. Its APIs include Sertraline HCI, Racecadotril, Palonosetron HCI, Silodosin, Solifenacin Succinate, Tamsulosin HCI, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Atazanavir, Rupatadine Fumarate, Glucosamine HCI, Glucosamine Sulfate KCL, Glucosamine Sulfate NaCl, Nitrofurantoin Monohydrate, Nitrofurantoin Anhydrous and Nitrofurantoin Macrocrystal and others. Its intermediates include 4-(3,4-Dichlorophenyl)-1-tetralone, 1-Benzylpiperidine-4-Carboxaldehyde (BPCA), 3-Hydroxymethyl quinuclidine Hcl, and others. Its chiral intermediates include S-(+)-3-Quinuclidinol, R-(-)-3-Quinuclidinol and others. The Company's nutraceuticals include Glucosamine Hydrochloride, Glucosamine Sulfate Potassium Chloride and Glucosamine Sulfate Sodium Chloride.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.41% | 21.94M | |
| +54.07% | 809B | |
| +38.59% | 621B | |
| -7.05% | 351B | |
| +15.44% | 319B | |
| +5.72% | 289B | |
| +13.40% | 238B | |
| +0.61% | 221B | |
| +13.24% | 218B | |
| +7.42% | 166B |
- Stock Market
- Equities
- TYCHE6 Stock
